Cord blood index predicts engraftment and early non-relapse mortality in adult patients with single-unit cord blood transplantation

• Published in: Bone marrow transplantation (Basingstoke) 2021-11, Vol.56 (11), p.2771-2778
• Main Authors: Kondo, Gaku, Ishimaru, Fumihiko, Konuma, Takaaki, Takahashi, Satoshi, Atsuta, Yoshiko, Ogawa, Atsuko, Minemoto, Mutsuko, Kashiwase, Koichi, Azuma, Fumihiro, Ito, Miyuki, Isoyama, Keiichi, Kobayashi, Takeshi, Ohashi, Kazuteru, Nakajima, Fumiaki, Hiruma, Kiyoshi, Makino, Shigeyoshi, Mugishima, Hideo, Namba, Noriko, Tsuno, Hirokazu, Nagai, Tadashi, Muroi, Kazuo, Nakajima, Kazunori
• Format: Article
• Language: English
• Subjects: 631/532/1542; 631/67/1990/283; Antigens; Antigens, CD34; Blood; CD34 antigen; Cell Biology; Cord blood; Cord Blood Stem Cell Transplantation; Fetal Blood; Graft Survival; Granulocytes; Health risk assessment; Hematology; Hematopoietic Stem Cell Transplantation; Histocompatibility antigen HLA; Humans; Internal Medicine; Leukocytes (granulocytic); Leukocytes (neutrophilic); Macrophages; Medicine; Medicine & Public Health; Methods; Mortality; Neutrophils; Public Health; Stem cell transplantation; Stem Cells; Transplantation
• ISSN: 0268-3369; 1476-5365
• DOI: 10.1038/s41409-021-01406-7

How to select optimal cord blood (CB) remains an important clinical question. We developed and validated an index of CB engraftment, the cord blood index (CBI), which uses three weighted variables representing cell doses and HLA mismatches. We modeled the neutrophil engraftment time with competing events by random survival forests for competing risks as a function of the predictors: total nucleated cells, CD34, colony-forming units for granulocytes/macrophages, and the number of HLA mismatches at the antigen and allele levels. The CBI defined three groups that had different neutrophil engraftment rates at day 30 (High, 83.7% [95% CI, 79.2–88.1%]; Intermediate, 77.0% [95% CI, 73.7–80.2%]; Low, 68.4% [95% CI, 63.6–73.2%]), platelet engraftment rates at day 60 (High, 70.4% [95% CI, 64.9–75.9%]; Intermediate, 62.3% [95% CI, 58.5–66.0%]; Low, 49.3% [95% CI, 44.2–54.5%]), and non-relapse mortality at day 100 (High, 14.1% [95% CI, 9.9–18.3%]; Intermediate, 16.4% [95% CI, 13.5–19.3%]; Low, 21.3% [95% CI, 17.1–25.5%]). This novel approach is clinically beneficial and can be adopted immediately because it uses easily obtained pre-freeze data of CB.